Cloud Banner

Pharmaceutical

Image

Global Neonatal Seizures Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Neonatal Seizures Drugs Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR - 3.4% Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 222.50 Million
Diagram Market Size (Forecast Year) USD 290.73 Million
Diagram CAGR 3.4%

Global Neonatal Seizures Drugs Market, By Type (Tonic Seizures, Clonic and Myoclonic Seizures, Non Paroxysmal Repetitive Behaviours), Drug (Dilantin, Phenobarbital, Other), Dosage (Tablets, Injection, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Neonatal Seizures Drugs Market

Market Analysis and Size

Due to the limited evidence available to help decide the appropriate usage of drugs for children of all ages with varied forms of epilepsy, doctors confront unique problems while treating children with epilepsy. However, progress has recently been made in understanding how antiepileptic medicines (AEDs) can be used to treat newborn seizures and infantile spasms, which are seizure disorders that occur in the first year of life. The efficacy of AEDs in treating these illnesses has been disputed, and predicting the fate of these problems for each kid has been challenging, so any advancement is welcome.

Data Bridge Market Research analyses that the neonatal seizures drugs? market was valued at USD 222.5 million in 2021 and is expected to reach USD 290.73 million by 2029, registering a CAGR of 3.40% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Tonic Seizures, Clonic and Myoclonic Seizures, Non Paroxysmal Repetitive Behaviours), Drug (Dilantin, Phenobarbital, Other), Dosage (Tablets, Injection, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (US), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (US), Johnson & Johnson Private Limited (US), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Surging drug approvals and launches

Market Definition

Seizures in neonates are aberrant electrical discharges in the central nervous system that typically appear as stereotyped muscle activity or autonomic abnormalities. Electroencephalography confirms the diagnosis, and further testing for reasons is recommended. Treatment is determined by the underlying cause. Seizures affect up to 1.4 percent of full-term new-borns and 20% of premature infants. Seizures could be a sign of a significant neonatal condition that has to be evaluated right away. The lack of myelination and insufficient creation of dendrites and synapses in neonates prevents generalization of electrical activity, hence most neonatal seizures are focal.

Neonatal Seizures Drugs Market Dynamics

Drivers

  • Increasing prevalence of hypoxia-ischemia

The rising prevalence of hypoxia-ischemia is anticipated to influence the neonatal seizures drugs? market's growth. The most prevalent cause of neonatal seizures is hypoxia-ischemia, which can occur before, during, or after delivery. Seizures of this nature can be severe and difficult to treat, but they usually subside after 3 to 4 days. Seizures may be less severe when new-born hypoxia is treated with therapeutic hypothermia (typically whole-body chilling), although they may recur upon rewarming.

  • Rising incidences of neonatal infections

The increasing incidences of neonatal infections is expected to flourish the market's growth rate during the forecast period of 2022-2029. Seizures can occur as a result of neonatal infections including meningitis and sepsis; in these cases, seizures are usually accompanied by other symptoms and signs. In neonates, group B streptococci and gram-negative bacteria are the most common causes of infection. Seizures can also be caused by encephalitis caused by the cytomegalovirus, herpes simplex virus, rubella virus, Treponema pallidum, Toxoplasma gondii, or Zika virus.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the neonatal seizures drugs? market. Additionally, rising healthcare expenditure and changing lifestyle of people will result in the expansion of neonatal seizures drugs? market. Along with this, rising prevalence rate of chronic disease such as thyroid, diabetes, and kidney disease, and favourable reimbursement policies will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the neonatal seizures drugs? market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of neonatal seizures drugs during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the neonatal seizures drugs? market. Additionally, the side effects of neonatal seizures drugs? will act as market restrain and further impede the market's growth rate during the forecast period of 2022-2029.

This neonatal seizures drugs? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neonatal seizures drugs? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Seizures in new-borns are a common neurological emergency. In terms new-borns, the incidence has been reported to range from 1 to 5.5 per 1000 live births, with greater rates recorded in preterm infants. In the United States, the incidence is estimated to be between 80 and 120 instances per 100,000 new-borns per year.

Neonatal seizures drugs? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Neonatal Seizures Drugs Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations, resulting from multiple precautionary lockdowns and other limitations imposed by governments all over the world. The neonatal seizures drugs market was no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors were likely to have a negative impact on the neonatal seizures drugs market's revenue trajectory. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.

Global Neonatal Seizures Drugs Market Scope

The neonatal seizures drugs? market is segmented on the basis of type, drug, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Tonic Seizures
  • Clonic and Myoclonic Seizures
  • Non Paroxysmal Repetitive Behaviours

Drug

  • Dilantin
  • Phenobarbital
  • Other

Dosage

  • Injection
  • Tablets
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Neonatal Seizures Drugs Market Regional Analysis/Insights

The neonatal seizures drugs? market is analysed and market size insights and trends are provided by country, type, drug, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the neonatal seizures drugs? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the neonatal seizures drugs? market because of the rising level of investment on research and development activities in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel themarket's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region. Also, surging prevalence of kidney diseases, thyroid and liver disorders and the number of generic medications will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Neonatal Seizures Drugs Market Share Analysis

The neonatal seizures drugs? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neonatal seizures drugs? market.

Some of the major players operating in the neonatal seizures drugs? market are:

  • Merck KGaA (Germany)
  • Eisai Co., Ltd. (Japan)
  • AstraZeneca (UK)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Abbott (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • WOCKHARDT (Mumbai)
  • Novo Nordisk A/S (Denmark)
  • Glenmark Pharmaceuticals Limited (India)
  • Cipla Inc. (US)
  • Bausch Health Companies Inc. (Canada)
  • Otsuka America Pharmaceutical, Inc. (US)
  • Johnson & Johnson Private Limited (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Sumitomo Corporation (Japan)
  • Biocon (India)  


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The market value for neonatal seizures drugs market is expected USD 290.73 million by 2029.
The neonatal seizures drugs market is to grow at a CAGR of 3.40% during the forecast period of 2022 to 2029
The major players operating in the Neonatal Seizures Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (US), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (US), Johnson & Johnson Private Limited (US), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India).
The major countries covered in the Neonatal Seizures Drugs Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials